Clinicopathological differences and survival benefit in ER+/PR+/HER2+ vs ER+/PR−/HER2+ breast cancer subtypes

被引：0
|
作者：
Wu Ding
Dengfeng Ye
Haifeng Chen
Yingli Lin
Zhian Li
Chuanjian Tu
机构：
[1] Shaoxing Second Hospital,Department of Oncological Surgery
[2] Shaoxing Vocational and Technical College,Department of Early Childhood Education
[3] Shaoxing University School of Medicine,Department of Clinical Medicine
[4] Shaoxing Second Hospital,Department of Surgery
来源：
Breast Cancer | 2024年 / 31卷
关键词：
Breast cancer subtype; ER; PR; HER2; Survival benefit; IPTW;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：295 / 304
页数：9
相关论文
共 50 条
  • [1] Clinicopathological differences and survival benefit in ER+/PR+/HER2+vs ER+/PR-/HER2+breast cancer subtypes
    Ding, Wu
    Ye, Dengfeng
    Chen, Haifeng
    Lin, Yingli
    Li, Zhian
    Tu, Chuanjian
    BREAST CANCER, 2024, 31 (02) : 295 - 304
  • [2] TPD52 is a prognostic biomarker and potential therapeutic target for ER+/PR+/HER2+ breast cancer
    Cheng, Xiaolin
    Li, Zhengdong
    Jia, Xiaoqing
    Fan, Zhiyuan
    He, Qizhi
    Zhuang, Zhigang
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (03)
  • [3] ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer
    Arciero, Cletus A.
    Guo, Yi
    Jiang, Renjian
    Behera, Madhusmita
    O'Regan, Ruth
    Peng, Limin
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2019, 19 (04) : 236 - 245
  • [4] Complex rearrangements fuel ER+ and HER2+ breast tumours
    Houlahan, Kathleen E.
    Mangiante, Lise
    Sotomayor-Vivas, Cristina
    Adimoelja, Alvina
    Park, Seongyeol
    Khan, Aziz
    Pribus, Sophia J.
    Ma, Zhicheng
    Caswell-Jin, Jennifer L.
    Curtis, Christina
    NATURE, 2025, : 510 - 518
  • [5] Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2-breast cancer subtypes
    Parise, Carol A.
    Caggiano, Vincent
    CANCER CAUSES & CONTROL, 2019, 30 (05) : 417 - 424
  • [6] Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2− breast cancer subtypes
    Carol A. Parise
    Vincent Caggiano
    Cancer Causes & Control, 2019, 30 : 417 - 424
  • [7] Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer
    Mahdi, Amira F.
    Ashfield, Niall
    Crown, John
    Collins, Denis M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (02)
  • [8] Multi-ligand modified PC@DOX-PA/EGCG micelles effectively inhibit the growth of ER+, PR+ or HER2+ breast cancer
    Wang, Xiaozhen
    He, Jiecheng
    Jiang, Siyuan
    Gao, Yifei
    Zhang, Ling-Kun
    Yin, Liang
    You, Rong
    Guan, Yan-Qing
    JOURNAL OF MATERIALS CHEMISTRY B, 2022, 10 (03) : 418 - 429
  • [9] ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer
    Yunbo Luo
    Qingyun Li
    Jiang Fang
    Chaoying Pan
    Lingxing Zhang
    Xia Xu
    Shuangqiang Qian
    Xiaobo Zhao
    Lingmi Hou
    Scientific Reports, 14
  • [10] Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer
    Bahnassy, Shaymaa
    Stires, Hillary
    Jin, Lu
    Tam, Stanley
    Mobin, Dua
    Balachandran, Manasi
    Podar, Mircea
    Mccoy, Matthew D.
    Beckman, Robert A.
    Riggins, Rebecca B.
    ENDOCRINOLOGY, 2023, 164 (12) : 1 - 15
12345